The identification of reduced triglyceride and total cholesterol levels in all three lipoprotein-starved diffuse glioma cell lines led us to investigate LXR agonists, which were initially developed to reduce cardiovascular disease by preventing lipoprotein uptake via induction of MYLIP (which encodes IDOL), an E3 ubiquitin ligase that mediates the degradation of LDLR and VLDLR, and by promoting cholesterol export via ABCA1 and ABCG1 membrane transporters [48]. This evidence concerns the gene ABCG1 and cardiovascular disorder.